Brief: Liquidia Announces Global Settlement Resolving All Pending Litigation With United Therapeutics, Ensuring Continued Commercialization Of Yutrepia In Pah
BRIEF-Liquidia Announces Global Settlement Resolving All Pending Litigation With United Therapeutics, Ensuring Continued Commercialization Of Yutrepia In Pah Liquidia Corporation LQDA.O:
LIQUIDIA ANNOUNCES GLOBAL SETTLEMENT RESOLVING ALL PENDING LITIGATION WITH UNITED THERAPEUTICS, ENSURING CONTINUED COMMERCIALIZATION OF YUTREPIA IN PAH
LIQUIDIA CORPORATION - SETTLEMENT FULLY RESOLVES SIX ONGOING LAWSUITS BETWEEN LIQUIDIA AND UNITED THERAPEUTICS
LIQUIDIA CORPORATION - TO PAY NET $380.70 MILLION IN INSTALLMENTS IN 2026 AND 2027
LIQUIDIA CORPORATION - TO PAY $175 MILLION TO UNITED THERAPEUTICS WITHIN 30 BUSINESS DAYS
LIQUIDIA CORPORATION - TERMINATES PROMOTIONAL AGREEMENT FOR TREPROSTINIL INJECTION
LIQUIDIA CORPORATION - YUTREPIA REMAINS AVAILABLE TO PAH PATIENTS WITHOUT DISRUPTION
LIQUIDIA CORPORATION - REMOVES PH-ILD INDICATION FROM YUTREPIA LABEL AND CEASES PROMOTION
Source text: ID:nGNX9cxvQg
Further company coverage: LQDA.O
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug